Joseph A. Sparano, MD, on HR+, HER2– Breast Cancer: Individualizing Prognosis and Predicting Treatment Success

December 16, 2020 By The ASCO Post Staff

Joseph A. Sparano, MD, of the Montefiore Medical Center and Albert Einstein College of Medicine, discusses the development and validation of a tool that integrates the 21-gene recurrence score and clinicopathologic features to individualize prognosis for distant recurrence and predict chemotherapy benefit in patients with early breast cancer with greater precision (Abstract GS4-10).

Related Content